| Company Name: |
Guangzhou Younan Technology Co., Ltd
|
| Tel: |
020-82000279 18988968278 |
| Email: |
YN_research@163.com |
| Products Intro: |
Product Name:SWTX-143
CAS:2766575-48-6
Purity:0.97 Package:5mg;10mg;25mg;50mg;100mg;250mg;500mg;1g
|
SWTX-143 manufacturers
- SWTX-143
-
- $2172.00 / 50mg
-
2025-10-27
- CAS:2766575-48-6
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | SWTX-143 Basic information |
| Product Name: | SWTX-143 | | Synonyms: | SWTX-143;2-Propenamide, N-[5-amino-1,2,3,4-tetrahydro-1-[4-(trifluoromethyl)phenyl]-3-quinolinyl]- | | CAS: | 2766575-48-6 | | MF: | C19H18F3N3O | | MW: | 361.36 | | EINECS: | | | Product Categories: | | | Mol File: | 2766575-48-6.mol |  |
| | SWTX-143 Chemical Properties |
| Boiling point | 578.662±50.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.336±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 13.963±0.20(predicted) | | form | Solid | | color | White to off-white |
| | SWTX-143 Usage And Synthesis |
| Uses | SWTX-143 is an orally active YAP/TAZ-TEAD inhibitor that binds to the palmitoylation pocket of all four TEAD isoforms. SWTX-143 causes irreversible and specific inhibition of the transcriptional activity of YAP/TAZ-TEAD and shows antitumor activity[1]. | | in vivo | SWTX-143 (10, 25, 50 mg/kg, p.o., once daily for 19 days) induces dose-dependent tumor reduction in the NCI-H226 xenograft nude mouse model without notable side effects[1]. | Animal Model: | NF2-deficient human mesothelioma (NCI-H226) xenograft BALB/c nude mice model | | Dosage: | 10, 25, and 50 mg/kg | | Administration: | Oral gavage (p.o.), once daily for 19 days | | Result: | Had little effect on tumor volume during the first week of dosing;
Resulted in significant dose-dependent reduction in tumor volume observed afterward;
Led to no significant weight loss at the end of dosing. |
| | IC 50 | YAP/TAZ-TEAD | | References | [1] Hanne Hillen, et al. A novel irreversible TEAD inhibitor, SWTX-143, blocks Hippo pathway transcriptional output and causes tumor regression in preclinical mesothelioma models. Mol Cancer Ther. 2023 Sep 23. DOI:10.1158/1535-7163.MCT-22-0681 |
| | SWTX-143 Preparation Products And Raw materials |
|